University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Lee-may Chen, M.D.

Gynecologic cancer surgeon

Dr. Lee-may Chen is the interim director of the division of Gynecologic Oncology and a cancer expert specializing in gynecologic malignancies. She has a particular interest in surgical and medical management of ovarian cancer. Her research focuses on early detection in women who are at high risk of developing gynecological cancer, symptom management and decision-making in the treatment of gynecologic cancers.

She earned a medical degree and completed an obstetrical and gynecological residency at the University of Michigan. She completed a fellowship in gynecologic oncology at UCLA Medical Center before joining UCSF Medical Center in 1999. She is an associate clinical professor of obstetrics, gynecology and reproductive sciences at UCSF.


Gynecologic Surgical Oncology
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-9600
New Patient Fax: (415) 885-7662

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Lee-may Chen

Additional Languages



University of Michigan School of Medicine 1992


University of Michigan Medical Center, Obstetrics and Gynecology 1996


UCLA and Cedar Sinai Medical Center, Gynecologic Oncology 1999

Selected Research and Publications

  1. Tinkle CL, Weinberg V, Chen LM, Littell R, Cunha JA, Sethi RA, Chan JK, Hsu IC. Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes. Int J Radiat Oncol Biol Phys. 2015 Aug 1; 92(5):1093-100.
  2. Makker V, Filiaci VL, Chen LM, Darus CJ, Kendrick JE, Sutton G, Moxley K, Aghajanian C. Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N. Gynecol Oncol. 2015 Jul; 138(1):24-9.
  3. Chapman JS, Jacoby V, Chen LM. Managing symptoms and maximizing quality of life after preventive interventions for cancer risk reduction. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):40-4.
  4. Fuh KC, Shin JY, Kapp DS, Brooks RA, Ueda S, Urban RR, Chen LM, Chan JK. Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecol Oncol. 2015 Mar; 136(3):491-7.
  5. Lancaster JM, Powell CB, Chen LM, Richardson DL. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015 Jan; 136(1):3-7.
  6. Usach I, Blansit K, Chen LM, Ueda S, Brooks R, Kapp DS, Chan JK. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. Am J Obstet Gynecol. 2015 Feb; 212(2):188.e1-6.
  7. Rabban JT, Calkins SM, Karnezis AN, Grenert JP, Blanco A, Crawford B, Chen LM. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome. Am J Surg Pathol. 2014 Jun; 38(6):793-800.
  8. Rabban JT, Garg K, Crawford B, Chen LM, Zaloudek CJ. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol. 2014 Jun; 38(6):729-42.
  9. Miaskowski C, Cooper BA, Melisko M, Chen LM, Mastick J, West C, Paul SM, Dunn LB, Schmidt BL, Hammer M, Cartwright F, Wright F, Langford DJ, Lee K, Aouizerat BE. Disease and treatment characteristics do not predict symptom occurrence profiles in oncology outpatients receiving chemotherapy. Cancer. 2014 Aug 1; 120(15):2371-8.
  10. Lefkowits C, W Rabow M, E Sherman A, K Kiet T, Ruskin R, Chan JK, Chen LM. Predictors of high symptom burden in gynecologic oncology outpatients: who should be referred to outpatient palliative care? Gynecol Oncol. 2014 Mar; 132(3):698-702.
  11. Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013 Oct 1; 11(10):1199-209.
  12. Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013 Oct 1; 19(19):5485-93.
  13. Lu KH, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM, Lynch H, Cornelison T, Boyd-Rogers S, Rubin M, Daniels MS, Conrad P, Milbourne A, Gershenson DM, Broaddus RR. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila). 2013 Aug; 6(8):774-81.
  14. Lin WT, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, Cedars M, Rosen M. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer. 2013 May 1; 119(9):1652-9.
  15. Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian cancer, version 3.2012. J Natl Compr Canc Netw. 2012 Nov 1; 10(11):1339-49.
  16. Cohen JG, Kiet T, Shin JY, Sherman AE, Hamilton CA, Brooks RA, Ueda SM, Chen LM, Kapp DS, Chan JK. Factors associated with publication of plenary presentations at the Society of Gynecologic Oncologists annual meeting. Gynecol Oncol. 2013 Jan; 128(1):128-31.
  17. Cohen JG, Sherman AE, Kiet TK, Kapp DS, Osann K, Chen LM, O'Sullivan PS, Chan JK. Characteristics of success in mentoring and research productivity - a case-control study of academic centers. Gynecol Oncol. 2012 Apr; 125(1):8-13.
  18. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J, Kaufman B. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012 Feb 1; 30(4):372-9.
  19. Venkat P, Chen LM, Young-Lin N, Kiet TK, Young G, Amatori D, Dasverma B, Yu X, Kapp DS, Chan JK. An economic analysis of robotic versus laparoscopic surgery for endometrial cancer: costs, charges and reimbursements to hospitals and professionals. Gynecol Oncol. 2012 Apr; 125(1):237-40.
  20. Ruskin R, Urban RR, Sherman AE, Chen LL, Powell CB, Burkhardt DH, Chen LM. Predictors of intensive care unit utilization in gynecologic oncology surgery. Int J Gynecol Cancer. 2011 Nov; 21(8):1336-42.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.